Vor Biopharma FY2030 EPS Estimate Decreased by HC Wainwright

Vor Biopharma Inc. (NASDAQ:VOR) – HC Wainwright cut their FY2030 EPS estimates for Vor Biopharma in a research report issued on Wednesday, August 12th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn $3.89 per share for the year, down from their previous estimate of $4.27. HC Wainwright has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Vor Biopharma’s current full-year earnings is ($2.51) per share.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11).

A number of other equities research analysts have also recently commented on VOR. Wall Street Zen cut shares of Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Weiss Ratings raised Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Tuesday. Finally, Wedbush boosted their target price on Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $43.38.

Vor Biopharma Price Performance

Vor Biopharma stock opened at $22.34 on Thursday. Vor Biopharma has a twelve month low of $6.50 and a twelve month high of $50.20. The firm has a 50 day moving average price of $18.18 and a 200-day moving average price of $15.91.

Institutional Investors Weigh In On Vor Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of VOR. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Vor Biopharma during the fourth quarter worth $36,000. Goldman Sachs Group Inc. raised its stake in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares during the period. XTX Topco Ltd bought a new stake in shares of Vor Biopharma during the 2nd quarter valued at $66,000. Chung Wu Investment Group LLC bought a new stake in shares of Vor Biopharma during the 4th quarter valued at $109,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new stake in Vor Biopharma during the 4th quarter worth about $134,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).